When to Stop Januvia (Sitagliptin) Before Surgery
Hold sitagliptin on the morning of surgery or procedure. This is the standard perioperative management for oral glucose-lowering agents other than metformin and SGLT2 inhibitors, which require longer discontinuation periods.
Evidence-Based Recommendation
The most recent American Diabetes Association guidelines 1, 2, 1 consistently recommend that other oral glucose-lowering agents (including DPP-4 inhibitors like sitagliptin) should be held the morning of surgery or procedure. This differs from:
- Metformin: Hold on the day of surgery 1, 2, 1
- SGLT2 inhibitors: Must be discontinued 3-4 days before surgery 1, 2, 1
Clinical Rationale
Why Morning-of-Surgery Timing is Appropriate:
Sitagliptin's pharmacokinetic profile supports same-day discontinuation:
- The drug has a relatively short half-life
- No significant risk of perioperative ketoacidosis (unlike SGLT2 inhibitors)
- No major concerns for lactic acidosis (unlike metformin in renal dysfunction)
- The FDA label 3 does not specify special perioperative precautions beyond general diabetes management
Supporting Research Evidence:
Research studies have examined sitagliptin's perioperative use with mixed results:
- A randomized trial in cardiac surgery patients 4 found that continuing sitagliptin perioperatively did not prevent hyperglycemia or reduce complications, though it did reduce insulin requirements on regular wards
- Another pilot study 5 demonstrated sitagliptin was safe and effective for inpatient management when used alone or with basal insulin
These studies suggest sitagliptin can be safely held without causing immediate glycemic deterioration, supporting the morning-of-surgery discontinuation approach.
Perioperative Management Algorithm
Day Before Surgery:
- Continue sitagliptin at usual dose
- Ensure patient follows standard preoperative fasting guidelines
Morning of Surgery:
- Hold sitagliptin dose
- Monitor blood glucose every 2-4 hours while NPO 1, 2
- Administer short- or rapid-acting insulin as needed for hyperglycemia
- Target perioperative glucose: 100-180 mg/dL (5.6-10.0 mmol/L) 1, 2
Postoperative Period:
- Resume sitagliptin once patient is eating and drinking normally
- Continue glucose monitoring
- May require temporary insulin therapy if significant hyperglycemia develops
Important Caveats
Insulin adjustments are more critical than oral agent timing:
- If patient is also on insulin, reduce basal insulin to 75-80% of usual dose (or 50% for NPH) 1, 2
- This insulin reduction is more important for preventing hypoglycemia than the timing of sitagliptin discontinuation
No special extended discontinuation needed:
- Unlike SGLT2 inhibitors (which require 3-4 days for ketoacidosis risk mitigation 6), sitagliptin does not carry this risk
- The morning-of-surgery hold is primarily to avoid medication administration during NPO status and allow for more precise insulin-based glucose control perioperatively
Consider individual surgical factors:
- For minor procedures with minimal fasting, some guidelines 7 suggest oral agents may not need to be held
- For major surgery with prolonged NPO status, the morning-of hold remains appropriate
The evidence consistently supports holding sitagliptin the morning of surgery as part of standard perioperative diabetes management, with resumption once oral intake is restored.